Outlook Therapeutics is a biopharma company focused on developing and commercializing LYTENAVA™ (bevacizumab gamma), the first ophthalmic bevacizumab approved in Europe and the is seeking approval in the US for the treatment of wet AMD.
Advertisement|Remove ads.